Daewon Pharmaceutical Co., Ltd. (003220.KS)
KRW 14020.0
(-1.2%)
KRW 14020.0
(-1.2%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 526.95 Billion KRW | 10.04% |
| 2022 | 478.88 Billion KRW | 35.21% |
| 2021 | 354.17 Billion KRW | 14.81% |
| 2020 | 308.5 Billion KRW | -2.93% |
| 2019 | 317.82 Billion KRW | 10.88% |
| 2018 | 286.65 Billion KRW | 7.98% |
| 2017 | 265.46 Billion KRW | 10.28% |
| 2016 | 240.72 Billion KRW | 11.35% |
| 2015 | 216.18 Billion KRW | 18.79% |
| 2014 | 181.98 Billion KRW | 14.54% |
| 2013 | 158.87 Billion KRW | 14.99% |
| 2012 | 138.16 Billion KRW | -0.51% |
| 2011 | 138.87 Billion KRW | -4.02% |
| 2010 | 144.69 Billion KRW | 24.81% |
| 2009 | 115.93 Billion KRW | 27.87% |
| 2008 | 90.65 Billion KRW | 21.92% |
| 2007 | 74.35 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 158.3 Billion KRW | 12.39% |
| 2024 Q2 | 137.95 Billion KRW | -12.85% |
| 2023 Q3 | 128.97 Billion KRW | -3.04% |
| 2023 Q2 | 133.03 Billion KRW | 7.21% |
| 2023 Q1 | 124.08 Billion KRW | 1.27% |
| 2023 FY | 526.95 Billion KRW | 10.04% |
| 2023 Q4 | 140.85 Billion KRW | 9.21% |
| 2022 Q1 | 117.05 Billion KRW | 15.95% |
| 2022 FY | 478.88 Billion KRW | 35.21% |
| 2022 Q2 | 117.04 Billion KRW | -0.01% |
| 2022 Q3 | 122.24 Billion KRW | 4.44% |
| 2022 Q4 | 122.53 Billion KRW | 0.24% |
| 2021 FY | 354.17 Billion KRW | 14.81% |
| 2021 Q1 | 74.99 Billion KRW | -3.19% |
| 2021 Q2 | 87.69 Billion KRW | 16.94% |
| 2021 Q4 | 100.95 Billion KRW | 11.53% |
| 2021 Q3 | 90.52 Billion KRW | 3.22% |
| 2020 Q1 | 80.6 Billion KRW | -7.63% |
| 2020 Q4 | 77.46 Billion KRW | 2.32% |
| 2020 Q3 | 75.7 Billion KRW | 1.32% |
| 2020 FY | 308.5 Billion KRW | -2.93% |
| 2020 Q2 | 74.71 Billion KRW | -7.3% |
| 2019 Q3 | 75.5 Billion KRW | -4.13% |
| 2019 FY | 317.82 Billion KRW | 10.88% |
| 2019 Q2 | 78.75 Billion KRW | 3.2% |
| 2019 Q4 | 87.26 Billion KRW | 15.58% |
| 2019 Q1 | 76.3 Billion KRW | -4.9% |
| 2018 Q3 | 64.57 Billion KRW | -8.63% |
| 2018 FY | 286.65 Billion KRW | 7.98% |
| 2018 Q1 | 71.17 Billion KRW | -2.4% |
| 2018 Q4 | 80.23 Billion KRW | 24.26% |
| 2018 Q2 | 70.66 Billion KRW | -0.72% |
| 2017 Q1 | 62.85 Billion KRW | -4.38% |
| 2017 Q4 | 72.92 Billion KRW | 11.9% |
| 2017 FY | 265.46 Billion KRW | 10.28% |
| 2017 Q3 | 65.16 Billion KRW | 1.01% |
| 2017 Q2 | 64.51 Billion KRW | 2.64% |
| 2016 FY | 240.72 Billion KRW | 11.35% |
| 2016 Q2 | 61.65 Billion KRW | 6.14% |
| 2016 Q1 | 58.08 Billion KRW | -6.02% |
| 2016 Q3 | 55.24 Billion KRW | -10.4% |
| 2016 Q4 | 65.73 Billion KRW | 19.0% |
| 2015 FY | 216.18 Billion KRW | 18.79% |
| 2015 Q1 | 50.88 Billion KRW | -2.42% |
| 2015 Q4 | 61.81 Billion KRW | 24.56% |
| 2015 Q3 | 49.62 Billion KRW | -7.89% |
| 2015 Q2 | 53.87 Billion KRW | 5.88% |
| 2014 Q2 | 43.43 Billion KRW | 0.72% |
| 2014 Q1 | 43.12 Billion KRW | -3.03% |
| 2014 FY | 181.98 Billion KRW | 14.54% |
| 2014 Q4 | 52.14 Billion KRW | 20.46% |
| 2014 Q3 | 43.28 Billion KRW | -0.34% |
| 2013 Q2 | 40.21 Billion KRW | 10.82% |
| 2013 Q3 | 37.91 Billion KRW | -5.7% |
| 2013 Q4 | 44.46 Billion KRW | 17.28% |
| 2013 FY | 158.87 Billion KRW | 14.99% |
| 2013 Q1 | 36.28 Billion KRW | -4.93% |
| 2012 Q3 | 33.21 Billion KRW | -7.4% |
| 2012 Q4 | 38.16 Billion KRW | 14.93% |
| 2012 FY | 138.16 Billion KRW | -0.51% |
| 2012 Q1 | 29.77 Billion KRW | 0.0% |
| 2012 Q2 | 35.86 Billion KRW | 20.46% |
| 2011 Q1 | 33.12 Billion KRW | -10.61% |
| 2011 Q2 | 35.82 Billion KRW | 8.14% |
| 2011 Q3 | 32.37 Billion KRW | -9.63% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 FY | 138.87 Billion KRW | -4.02% |
| 2010 Q2 | 37 Billion KRW | 8.37% |
| 2010 Q1 | 34.14 Billion KRW | -0.15% |
| 2010 FY | 144.69 Billion KRW | 24.81% |
| 2010 Q3 | 36.48 Billion KRW | -1.39% |
| 2010 Q4 | 37.06 Billion KRW | 1.58% |
| 2009 Q4 | 34.19 Billion KRW | 17.5% |
| 2009 FY | 115.93 Billion KRW | 27.87% |
| 2009 Q3 | 29.1 Billion KRW | 3.77% |
| 2009 Q2 | 28.04 Billion KRW | 14.09% |
| 2009 Q1 | 24.58 Billion KRW | -2.51% |
| 2008 Q3 | 22.41 Billion KRW | 0.51% |
| 2008 Q2 | 22.3 Billion KRW | 7.58% |
| 2008 Q1 | 20.72 Billion KRW | -0.05% |
| 2008 FY | 90.65 Billion KRW | 21.92% |
| 2008 Q4 | 25.21 Billion KRW | 12.5% |
| 2007 FY | 74.35 Billion KRW | 0.0% |
| 2007 Q4 | 20.73 Billion KRW | 18.31% |
| 2007 Q3 | 17.53 Billion KRW | -7.07% |
| 2007 Q2 | 18.86 Billion KRW | 9.54% |
| 2007 Q1 | 17.22 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -284.049% |
| Dong-A Socio Holdings Co., Ltd. | 1132 Billion KRW | 53.45% |
| Ildong Holdings Co., Ltd. | 638.44 Billion KRW | 17.464% |
| HANDOK Inc. | 522.74 Billion KRW | -0.806% |
| Kukje Pharma Co., Ltd. | 135.37 Billion KRW | -289.26% |
| Yuhan Corporation | 1858.98 Billion KRW | 71.654% |
| Dong-A ST Co., Ltd. | 663.98 Billion KRW | 20.637% |
| SAMSUNG PHARM. Co., LTD. | 51.95 Billion KRW | -914.246% |
| Hanmi Pharm. Co., Ltd. | 1490.88 Billion KRW | 64.655% |
| Hanall Biopharma Co.,Ltd | 134.9 Billion KRW | -290.596% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | -42.213% |
| Dong Sung Bio Pharm.Co.,Ltd. | 88.59 Billion KRW | -494.797% |
| MYUNGMOON Pharm co.,Ltd | 169.56 Billion KRW | -210.763% |
| Hana Pharm Co., Ltd. | 224.45 Billion KRW | -134.768% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -284.049% |
| Ilsung Pharmaceuticals Co., Ltd. | 78.05 Billion KRW | -575.119% |
| REYON Pharmaceutical Co., Ltd. | 151.07 Billion KRW | -248.811% |
| Aprogen pharmaceuticals,Inc. | 87.36 Billion KRW | -503.171% |
| JW Holdings Corporation | 928.07 Billion KRW | 43.221% |
| Ildong Pharmaceutical Co., Ltd. | 600.75 Billion KRW | 12.285% |
| Chong Kun Dang Pharmaceutical Corp. | 1669.4 Billion KRW | 68.435% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 29.601% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -163.175% |
| Hyundai Pharmaceutical Co., Ltd. | 180.76 Billion KRW | -191.516% |
| Samil Pharmaceutical Co.,Ltd | 196.34 Billion KRW | -168.38% |
| Jeil Pharmaceutical Co.,Ltd | 726.39 Billion KRW | 27.456% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -284.049% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1514.45 Billion KRW | 65.205% |
| Daewoong pharmaceutical Co.,Ltd | 1375.32 Billion KRW | 61.685% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 29.601% |
| Yuhan Corporation | 1858.98 Billion KRW | 71.654% |
| Jeil Pharma Holdings Inc | 794.71 Billion KRW | 33.693% |
| Yungjin Pharm. Co., Ltd. | 234.9 Billion KRW | -124.328% |
| Suheung Co., Ltd. | 594.56 Billion KRW | 11.372% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 29.601% |
| Samjin Pharmaceuticals Co., Ltd. | 292.12 Billion KRW | -80.384% |
| Korea United Pharm Inc. | 278.94 Billion KRW | -88.91% |
| CKD Bio Corp. | 160.35 Billion KRW | -228.62% |
| Dongwha Pharm.Co.,Ltd | 361.1 Billion KRW | -45.926% |
| Whan In Pharm Co.,Ltd. | 230.39 Billion KRW | -128.718% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -163.175% |
| Chong Kun Dang Holdings Corp. | 879.78 Billion KRW | 40.104% |
| Boryung Corporation | 859.62 Billion KRW | 38.7% |
| Bukwang Pharmaceutical Co., Ltd. | 125.92 Billion KRW | -318.454% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | -42.213% |
| JW Lifescience Corporation | 206.86 Billion KRW | -154.738% |